Pharma Reaserch Prod Co Ltd

KQ:214450 Korea Biotechnology
Market Cap
$2.27 Billion
₩3.32 Trillion KRW
Market Cap Rank
#6519 Global
#127 in Korea
Share Price
₩320000.00
Change (1 day)
+3.90%
52-Week Range
₩288000.00 - ₩711000.00
All Time High
₩711000.00
Categories
Companies in Korea Biotechnology
About

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more

Pharma Reaserch Prod Co Ltd (214450) - Net Assets

Latest net assets as of September 2025: ₩688.78 Billion KRW

Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) has net assets worth ₩688.78 Billion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩988.30 Billion) and total liabilities (₩299.53 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩688.78 Billion
% of Total Assets 69.69%
Annual Growth Rate 15.41%
5-Year Change 132.02%
10-Year Change N/A
Growth Volatility 9.41

Pharma Reaserch Prod Co Ltd - Net Assets Trend (2015–2024)

This chart illustrates how Pharma Reaserch Prod Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Pharma Reaserch Prod Co Ltd (2015–2024)

The table below shows the annual net assets of Pharma Reaserch Prod Co Ltd from 2015 to 2024.

Year Net Assets Change
2024-12-31 ₩569.44 Billion +23.20%
2023-12-31 ₩462.19 Billion +34.55%
2022-12-31 ₩343.50 Billion +12.46%
2021-12-31 ₩305.44 Billion +24.46%
2020-12-31 ₩245.42 Billion +17.39%
2019-12-31 ₩209.07 Billion +5.79%
2018-12-31 ₩197.62 Billion +10.50%
2017-12-31 ₩178.85 Billion +4.20%
2016-12-31 ₩171.64 Billion +9.50%
2015-12-31 ₩156.75 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Pharma Reaserch Prod Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 884.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩343.06 Billion 63.60%
Common Stock ₩5.25 Billion 0.97%
Other Components ₩191.09 Billion 35.43%
Total Equity ₩539.40 Billion 100.00%

Pharma Reaserch Prod Co Ltd Competitors by Market Cap

The table below lists competitors of Pharma Reaserch Prod Co Ltd ranked by their market capitalization.

Company Market Cap
Frontken Corporation Bhd
KLSE:0128
 		$1.22 Billion
Zhejiang Chengchang Technology Co. Ltd.
SHE:001270
 		$1.22 Billion
Gibraltar Industries Inc
NASDAQ:ROCK
 		$1.22 Billion
CITIC Guoan Information Industry Co Ltd
SHE:000839
 		$1.22 Billion
Construcciones y Auxiliar de Ferrocarriles S.A.
MC:CAF
 		$1.22 Billion
Hebei Sinopack Electronic Technolog
SHE:003031
 		$1.22 Billion
WILEY (JOHN) + SONS B
F:2F70
 		$1.22 Billion
IIFL Finance Limited
NSE:IIFL
 		$1.22 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pharma Reaserch Prod Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 433,103,640,210 to 539,402,310,120, a change of 106,298,669,910 (24.5%).
  • Net income of 92,043,313,170 contributed positively to equity growth.
  • Dividend payments of 10,090,447,450 reduced retained earnings.
  • Share repurchases of 199,999,891,990 reduced equity.
  • New share issuances of 199,999,891,990 increased equity.
  • Other factors increased equity by 24,345,804,190.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩92.04 Billion +17.06%
Dividends Paid ₩10.09 Billion -1.87%
Share Repurchases ₩200.00 Billion -37.08%
Share Issuances ₩200.00 Billion +37.08%
Other Changes ₩24.35 Billion +4.51%
Total Change ₩- 24.54%

Book Value vs Market Value Analysis

This analysis compares Pharma Reaserch Prod Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 6.14x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 17.53x to 6.14x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩18256.70 ₩320000.00 x
2017-12-31 ₩19149.48 ₩320000.00 x
2018-12-31 ₩20891.66 ₩320000.00 x
2019-12-31 ₩22197.68 ₩320000.00 x
2020-12-31 ₩25424.35 ₩320000.00 x
2021-12-31 ₩30617.97 ₩320000.00 x
2022-12-31 ₩34433.26 ₩320000.00 x
2023-12-31 ₩42492.31 ₩320000.00 x
2024-12-31 ₩52145.39 ₩320000.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pharma Reaserch Prod Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 17.06%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 26.29%
  • • Asset Turnover: 0.41x
  • • Equity Multiplier: 1.59x
  • Recent ROE (17.06%) is above the historical average (11.40%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 8.22% 34.38% 0.22x 1.08x ₩-2.80 Billion
2016 8.10% 30.27% 0.26x 1.04x ₩-3.26 Billion
2017 7.24% 23.78% 0.29x 1.06x ₩-4.93 Billion
2018 7.29% 22.41% 0.25x 1.31x ₩-5.35 Billion
2019 7.97% 19.87% 0.31x 1.29x ₩-4.24 Billion
2020 13.35% 30.14% 0.34x 1.30x ₩8.23 Billion
2021 15.29% 30.30% 0.36x 1.40x ₩16.14 Billion
2022 11.81% 20.83% 0.41x 1.39x ₩6.23 Billion
2023 17.68% 29.33% 0.49x 1.24x ₩33.24 Billion
2024 17.06% 26.29% 0.41x 1.59x ₩38.10 Billion

Industry Comparison

This section compares Pharma Reaserch Prod Co Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $209,689,906,881
  • Average return on equity (ROE) among peers: -10.47%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Pharma Reaserch Prod Co Ltd (214450) ₩688.78 Billion 8.22% 0.43x $1.22 Billion
ORIENTBIO Inc. (002630) $67.35 Billion -2.60% 1.21x $28.10 Million
Green Cross (005250) $282.15 Billion 18.83% 0.53x $228.88 Million
Green Cross Holdings Preference Shares (005257) $1.44 Trillion 3.01% 0.78x $410.72 Million
Pharmicell (005690) $9.90 Billion -119.73% 2.00x $438.14 Million
GeneOne Life Science Inc (011000) $39.74 Billion 0.00% 0.49x $53.78 Million
HLB Co. Ltd (028300) $77.24 Billion -21.40% 1.44x $4.11 Billion
Daesung Microbiological Labs. Co. Ltd (036480) $25.09 Billion 18.13% 0.29x $14.92 Million
Seoulin Bioscience Co.Ltd (038070) $51.49 Billion 4.00% 0.38x $27.72 Million
Hyundai Bioscience Co. Ltd (048410) $39.30 Billion 0.00% 0.56x $899.28 Million
iNtRON Biotechnology Inc (048530) $64.96 Billion -4.91% 0.37x $83.99 Million